Jun 2022 $1 M No. 5 Under $2 million 9
Thetis Pharmaceuticals LLC: Raise no. 5, Jun 2022 × Investors in this round 9 investors had bought by the notice of Jul 11, 2022: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $2 M offered; $1 M still to sell
Smallest investment taken $10,000
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Connecticut People named in the notice Gary Mathias · Executive Officer, Director · Manager Cynthia F. Green · Director · Manager Dennis F. Willson · Director · Manager Frank C. Sciavolino · Director · Manager Walter Ogier · Director · Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gary Mathias, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2022. Read the notice at the SEC .
debt, options SEC Jun 2016 $4 M No. 4 $2 to $10 million 52
Thetis Pharmaceuticals LLC: Raise no. 4, Jun 2016 × Investors in this round 52 investors had bought by the notice of Jan 17, 2017: 52 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $8 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $200,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Limited Liability Company, incorporated in Connecticut People named in the notice Frank C Sciavolino · Executive Officer, Director · Manager, President and Chief Scientific Officer Gary F Mathias · Executive Officer, Director · Manager & Chief Executive Officer David M Wurzer · Director · Manager Dennis F Willson · Director · Manager Walter F Ogier · Director · Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Fairport Capital, Inc. (CRD 15034) · broker-dealer Fairport Capital, Inc. (CRD 15034) · Scottsdale, Arizona Sold in all US states Remarks in the notice On fees: “Broker will be paid a commission of 5% cash and 1.5% equity of total amount sold through broker.”On the use of proceeds: “No payments other than ordinary course employment compensation is being paid to officers or managers.”Signed by Gary F. Mathias, Manager & CEO. Source: SEC Form D and 1 amendment, newest notice filed Jan 17, 2017. Read the notice at the SEC .
equity, options SEC Jan 2016 $1 M No. 3 Under $2 million 16
Thetis Pharmaceuticals LLC: Raise no. 3, Jan 2016 × Investors in this round 16 investors had bought by the notice of Feb 11, 2016: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $4 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Connecticut People named in the notice Gary F Mathias · Executive Officer, Director · Manager & Chief Executive Officer Alan F Mendelson · Director · Manager David M Wurzer · Director · Manager Dennis M Willson · Director · Manager Frank C Sciavolino · Director · Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “No payments other than ordinary course employment compensation is being paid to officers or managers.”Signed by Gary F. Mathias, Manager & CRO. Source: SEC Form D, newest notice filed Feb 11, 2016. Read the notice at the SEC .
debt, options SEC Dec 2012 $6 M No. 2 $2 to $10 million 32
Thetis Pharmaceuticals LLC: Raise no. 2, Dec 2012 × Investors in this round 32 investors had bought by the notice of Dec 18, 2012: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $7 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Connecticut People named in the notice Gary F Mathias · Executive Officer, Director · Manager & Chief Financial Officer Michael M Carter · Executive Officer · Secretary Alan F Mendelson · Director · Manager David M Wurzer · Director · Manager Dennis M Willson · Director · Manager Frank C Sciavolino · Director · Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gary F. Mathias, Manager & CFO. Source: SEC Form D, newest notice filed Dec 18, 2012. Read the notice at the SEC .
equity SEC Aug 2011 $2 M No. 1 Under $2 million 14
Thetis Pharmaceuticals LLC: Raise no. 1, Aug 2011 × Investors in this round 14 investors had bought by the notice of Aug 26, 2011: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Connecticut People named in the notice Frank C. Sciavolino · Executive Officer, Director · Manager Gary F. Mathias · Executive Officer · Manager Alan F. Mendelson · Director · Manager David M. Wurzer · Director · Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gary F. Mathias, Manager, CFO, Tres. and Sec.. Source: SEC Form D, newest notice filed Aug 26, 2011. Read the notice at the SEC .
debt, options SEC